Godrej Agrovet Limited has informed the Exchange regarding Board meeting held on August 06, 2025.
GODREJAGRO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godrej Agrovet's Board approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025) with a clean (unmodified) limited review report from B S R & Co. LLP. On a standalone basis, revenue from operations rose to Rs 2,006.56 crore from Rs 1,741.48 crore (~15% YoY), while profit for the period grew to Rs 168.89 crore from Rs 136.39 crore (~24% YoY). On a consolidated basis, revenue stood at Rs 2,614.29 crore (vs Rs 2,350.75 crore) and net profit was Rs 148.83 crore (vs Rs 131.63 crore). Standalone operating margin expanded sharply from 8.42% to 12.90% YoY, driven mainly by the Vegetable Oil segment whose revenue nearly doubled to Rs 499.13 crore. The company acquired the remaining 36.79% stake in Creamline Dairy (taking holding to 99.67%) for Rs 708.58 crore and participated in its subsidiary Astec LifeSciences' Rs 249.35 crore rights issue, raising its stake there to 67.03%.
Strong margin expansion and double-digit profit growth in Q1 FY26 are positive signals for shareholders, though the headline revenue growth is solid but not exceptional. The Dairy and Poultry segments saw mild revenue softness, while Vegetable Oil and Crop Protection were the standout performers. The large Creamline Dairy buyout and Astec rights issue indicate active capital allocation that may dilute near-term returns but strengthens the consolidated group structure.